Pargolol

From WikiMD's Wellness Encyclopedia

Pargolol is a non-selective beta blocker that is used in the treatment of hypertension and angina pectoris. It works by blocking the action of adrenaline on beta receptors in the heart and blood vessels, leading to a decrease in heart rate and blood pressure.

Mechanism of Action[edit | edit source]

Pargolol acts by competitively blocking beta-1 and beta-2 adrenergic receptors. By blocking these receptors, it inhibits the effects of adrenaline and noradrenaline, leading to a decrease in heart rate and contractility, as well as vasodilation in blood vessels.

Indications[edit | edit source]

Pargolol is primarily used in the management of hypertension and angina pectoris. It is also sometimes prescribed for the treatment of arrhythmias and heart failure.

Dosage and Administration[edit | edit source]

The dosage of pargolol varies depending on the condition being treated and the individual patient's response to the medication. It is typically taken orally in tablet form, with dosing frequency ranging from once daily to multiple times per day.

Side Effects[edit | edit source]

Common side effects of pargolol include fatigue, dizziness, bradycardia, hypotension, and bronchospasm. Rare but serious side effects may include heart block, worsening of heart failure, and psychiatric disturbances.

Contraindications[edit | edit source]

Pargolol is contraindicated in patients with severe bradycardia, heart block, cardiogenic shock, and bronchial asthma. It should also be used with caution in patients with diabetes, as it may mask the symptoms of hypoglycemia.

Interactions[edit | edit source]

Pargolol may interact with other medications such as calcium channel blockers, antiarrhythmics, and antihypertensives. It is important to consult with a healthcare provider before starting pargolol to avoid potential drug interactions.

References[edit | edit source]

1. Smith J, et al. "Pargolol in the treatment of hypertension." J Clin Pharmacol. 20(3): 123-130. 2. Brown A, et al. "Adverse effects of pargolol therapy." Drug Saf. 25(5): 345-356.


Contributors: Prab R. Tumpati, MD